Hi Moein: The Pfizer drug is different from the ACE 031 drug--it is more specific in it's activity and you might predict that it's less likely there will be the kind of side effects that were seen in the ACE 031 trial, but that's speculation on my part.
Moein, I don't believe the company has released any results from the healthy volunteer study.
When we were talking to our Neurologist earlier this month, she said that the boys that were on a previous myostatin inhibitor trial (not sure if it was ACE 031) were doing very well, and she seemed optimistic about this one.
Yes, supposedly it is more specific in how it blocks myostatin, which in theory should give similar results with fewer side effects.
Sorry David, I really can't speculate. If Pfizer hasn't made something public its generally because they are not yet ready to talk about it.